ArticleGlomerular diseases
Acute Care Visits and Subsequent Health-Related Quality of Life among Children and Adults with Glomerular Disease in the Cure Glomerulonephropathy Cohort.
Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Introduction: Health-related quality of life (HRQOL) is an important patient-reported aspect of overall health and is understudied in patients with glomerular disease (GD). Conflicting data have emerged regarding whether acute care visits (ACVs) are associated with HRQOL. This report describes types of ACVs and their short-term impact on HRQOL in patients with minimal change disease (MCD), IgA nephropathy/vasculitis (IgAN/IgAV), focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN). Methods: The Cure Glomerulonephropathy (CureGN) network is an observational prospective cohort study that has enrolled children and adults diagnosed with MCD, FSGS, MN, or IgAN/IgAV from 71 clinical centers across the USA, Canada, and Europe since December 2014. We used linear mixed-effects models to examine the association between frequency of ACVs over a 3-month period and subsequent Patient-Reported Outcomes Measurement Information System (PROMIS) scores, accounting for previous PROMIS scores, clinical characteristics, medication use, comorbid conditions, and socioeconomic indicators. Results: The study included 2,393 patients, 1,282 of whom experienced at least 1 ACV with a total of 3,555 ACVs (33.3 per 100 person-years) observed during CureGN study follow-up. The most frequent ACV-related diagnoses were categorized as infectious, gastrointestinal, hypertensive, or cardiovascular in origin. Two additional ACVs were associated with clinically and statistically significantly worse general physical health among adults; self-reported fatigue, mobility, and global health in children; and parent-reported fatigue, mobility, and global health in children. Only one additional ACV was associated with clinically and significantly worse fatigue among patients with cyclophosphamide exposure and parent-reported mobility among children ages 8-<11. Conclusions: Increasing ACV burden was associated with lower HRQOL across multiple physical health domains for patients with GD. Our study reinforces the health care burden experienced by patients with GD and identifies risk factors for deterioration in HRQOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.